Ropes & Gray represented Foghorn Therapeutics in its registered direct offering of 12,743,039 shares of common stock $5.51 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to an aggregate of 7,220,794 shares of its common stock for total gross proceeds of approximately $110 million. The closing was announced in a May 22 press release.
Foghorn is a Cambridge, Mass., biopharmaceutical company developing a novel class of oncology medicines that target genetically-determined dependencies within the chromatin regulatory system.
The Ropes & Gray team included capital markets partner Rachel Phillips, life sciences partner Marc Rubenstein, tax partner Eric Behl-Remijan, and life sciences regulatory & compliance partner Kellie Combs.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
